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Inflammatory cells orchestrate post-ischemic cardiac remodeling after
myocardial infarction (MI). Studies in Kit mutant mice suggest key roles for
mast cells in post-ischemic tissue remodeling. However, Kit mutations affect
multiple cell types of both immune and non-immune origin. The aim of this
study was to address the impact of mast cells on cardiac function following
MI, using selectively mast cell-deficient mice (Cpa3Cre/+ mice).
The number of mast cell progenitor (Lin-CD45+CD34+FcγRII/III+β7+)
increased in the bone marrow and the white adipose tissue on day 3 after MI,
infiltrated the heart on day 5 and differentiated to mature mast cells
(Cd117+FcεRI+Sca1+) by day 7 in cardiac tissue. To assess the functional
effect of mast cell infiltration, the cardiac function 14 days following MI
was assessed in wild-type (WT) and 3 mast cells deficient mice models,
the kitW/Wv mice, the Cpa3Cre/+ mice and mice treated with the degranulation
inhibitor DSCG (50 μg/g, once a day). There was a significant decrease of
the left ventricular shortening fraction in all 3 mast cell deficient models
compared to WT mice (1.4-, 1.6- and 2-fold respectively) that correlated
with increased cardiomyocyte apoptosis in the kitW/Wv mice; and increased
fibrosis in the DSCG-treated mice (n=8-14 per group, p<0.01 vs WT). Inter-
estingly, in the Cpa3Cre/+ mice there were no differences on post-MI cardiac
remodeling, but instead we observed a significant reduction in cardiomyo-
cyte contractility (both cell shortening and maximal contracting velocity)
with no effect on Ca2+ transient peak or sarcoplasmic reticulum load.
This work re-evaluates existing mast-cell deficient models on their effect
on cardiac remodeling and identifies a novel function for mast cells on mod-
ulation of cardiomyocyte contractility, Ca2+ cycling independently. Identifica-
tion of the molecular regulators involved in the cardiac effect of mast cell will
provide a new platform of regulators with potential therapeutic properties.
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Bcl11b/CTIP2, a zinc finger transcriptional repressor, interacts with the
RNApolymeraseII regulatory complex pTefb and exert an inhibitory action on
it. It is also implicated in the regulation of stem cells. Genetic variations in its
locus is associated with increased risk for cardiovascular disease making it rel-
evant to study the role of Bcl11b in the heart. Using knockdown/overexpres-
sion strategies, we showed that Bcl11b overexpression leads to increased
hypertrophic response while its overexpression induces opposite effects. To
study its role in vivo, we will use cardiac specific knock out mice and analyse
the effect on cardiac remodelling and stem cells. This study will allow us to
gain further insights into the molecular mechanisms that control cardiac
hypertrophy and cardiac stem cell commitment.
April 25th, Friday 2014

